Browse the evidence

Monounsaturated fat (MUFA) intake has a significant but weak correlation with multiple obesity and coronary indices (CI, AVI, BRI, WWI, AIP), suggesting a less pronounced impact on these specific metrics compared to SFA and PUFA.

In this study, monounsaturated fat (MUFA) intake was weakly correlated with various obesity and heart health markers. While MUFA is generally considered healthy, this study suggests its direct impact on these specific abdominal and coronary indices is less strong than that of saturated or polyunsaturated fats in this population.

Long-term intermittent fasting (IF) protocols, particularly time-restricted eating (TRE) with short windows (e.g., 8 hours), are associated with increased cardiovascular disease (CVD) mortality and adverse cardiac structural changes, primarily mediated by lean mass loss, circadian misalignment, and reward-based poor dietary choices.

If you practice intermittent fasting, be aware that long-term use (especially with very short eating windows like 8 hours) may increase your risk of heart disease and mortality, particularly if you have existing heart conditions or genetic risks. The benefits seen in short-term studies (less than 12 weeks) do not necessarily translate to long-term health. Focus on preserving muscle mass, eating nutrient-dense foods, and consider combining fasting with exercise or switching to a Mediterranean diet for better long-term cardiovascular outcomes.

Neuropilin-1 (NRP-1) plasma levels are inversely associated with fasting plasma triglycerides, and changes in NRP-1 during exercise are inversely correlated with changes in triglycerides.

This paper identifies a new potential biomarker, Neuropilin-1 (NRP-1), which is linked to triglyceride levels. While not a direct treatment, monitoring NRP-1 might help understand how exercise affects lipid metabolism in MetS patients. Lower NRP-1 changes are associated with greater triglyceride reductions.

Low-Carbohydrate High-Fat (LCHF) and Ketogenic diets do not significantly alter ALT levels in individuals with MASLD compared to control diets.

Current evidence from this meta-analysis does not support LCHF or Ketogenic diets as significantly effective for lowering liver enzymes (ALT) in people with MASLD compared to control diets. The wide variation in how 'low-carb' was defined across studies makes it difficult to draw firm conclusions, but it did not show the significant benefits seen with fasting or MedDiet.

Omega-3 fatty acid supplementation does not significantly alter ALT levels in individuals with MASLD.

Taking Omega-3 fatty acid supplements does not significantly lower liver enzymes (ALT) in people with MASLD compared to control groups. While Omega-3s are generally healthy, they should not be relied upon as a primary treatment for improving liver health biomarkers in this condition.

GLP-1 receptor agonist therapy improves tear production and tear film stability in patients with type 2 diabetes compared to non-GLP-1 RA therapies.

If you have Type 2 Diabetes and are considering or using GLP-1 RAs (like semaglutide or dulaglutide), this research suggests these medications might actually help keep your eyes moist and stable compared to other diabetes drugs. While this doesn't replace standard dry eye treatments, it is a potential benefit to discuss with your doctor, especially if you suffer from dry eye symptoms.

Endoscopic Bariatric Procedures (EBP), including intragastric balloon (IGB), aspiration therapy (AT), and primary obesity surgery endoluminal (POSE), are generally less effective than newer OMMs (semaglutide, tirzepatide) and have limited long-term data.

Endoscopic procedures (IGB, AT, POSE, ESG) offer moderate weight loss (3.8-12.8% TBWL) in the short term but are generally less effective than newer medications (semaglutide, tirzepatide) and lack long-term efficacy data. They may be considered for patients who are not candidates for surgery or high-dose medications, but they are not the most effective option for significant, sustained weight loss.

Network pharmacology analysis suggests that the synergistic mechanism of combined exercise and medication involves the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network.

This is a mechanistic hypothesis. It suggests that combining exercise and medication may work by reducing inflammation (IL1B-STAT3) and improving lipid metabolism (SIRT1/CD36).

Dual GLP-1/glucagon agonists (e.g., cotadutide, pemvidutide) provide greater reductions in liver fat and fibrosis markers than GLP-1 mono-agonists, likely due to glucagon-mediated mitochondrial turnover and glycogenolysis.

If GLP-1 mono-agonists (like semaglutide) are not enough, dual agonists (like cotadutide or pemvidutide) may offer greater liver fat reduction and fibrosis improvement. However, these drugs are more complex and may cause more side effects. They are currently in clinical trials and not yet standard care. Discuss with your hepatologist if you are a candidate for these newer agents, especially if you have significant liver fat but stable diabetes.

Semaglutide use is associated with a high incidence of gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, with signal strength varying by clinical priority and time-to-onset.

If you are taking semaglutide, expect gastrointestinal side effects like nausea, vomiting, or diarrhea, especially when starting or increasing the dose. These are common and often decrease over time. Discuss starting with a lower dose and titrating slowly with your provider to improve tolerance. Ensure you stay hydrated and eat smaller, bland meals if symptoms occur.

Six months of once-weekly GLP-1 analogue (semaglutide) therapy restores natural killer (NK) cell effector function (cytotoxicity and cytokine production) in people with obesity, independent of weight loss.

For people with obesity, GLP-1 therapy (like semaglutide) may strengthen the immune system's ability to fight viruses and cancer, independent of how much weight is lost. This suggests benefits beyond just metabolic health.

GLP-1 therapy restores NK cell metabolism by upregulating the CD98-mTOR-glycolysis axis, which is critical for NK cell cytokine production.

GLP-1 therapy helps fix the 'metabolic engine' of immune cells (NK cells) in obese individuals, allowing them to produce necessary defense chemicals (cytokines) more effectively.

GLP-1 receptor agonists should be discontinued prior to metabolic bariatric surgery to prevent delayed gastric emptying and aspiration pneumonia during anesthesia.

If you take GLP-1 medications (like Ozempic or Saxenda) and are having bariatric surgery, you MUST stop them before the procedure. Daily users should stop on the day of surgery; weekly users should stop one week prior. This prevents life-threatening aspiration pneumonia.

High-volume and high-intensity exercise may increase the risk of atrial fibrillation (AF) in athletes, suggesting a J-shaped relationship between exercise volume and AF risk.

While exercise is crucial for heart health, extremely high volumes of intense exercise may increase the risk of atrial fibrillation in athletes. Aim for moderate-volume exercise (5-20 MET hours/week) for optimal protection against AF.

Manipulations of resistance training variables (such as volume, intensity, or frequency) have a negligible impact on muscle fiber hypertrophy compared to intrinsic biological factors.

Stop obsessing over perfecting your set and rep schemes. Your genetic and biological response to training is the main driver of muscle growth, not whether you do 8 reps or 12. Focus on consistent, hard training and recovery rather than constantly changing variables.

Adipose-derived mesenchymal stem cell (ADMSC) therapy reduces body weight and improves metabolic complications (diabetes, NAFLD) in animal models, though clinical efficacy remains controversial due to low cell survival rates.

ADMSC therapy shows promise in reducing weight and improving metabolic health in animal studies, but it is not yet a standard or proven treatment for humans. Clinical efficacy is controversial, and cell survival after transplantation is low. Patients should not expect this to be a current standard of care.

Geroscience aims to compress the period of morbidity by targeting the fundamental biological mechanisms of aging, rather than treating individual age-related diseases in isolation.

This paper outlines a research strategy, not a direct lifestyle intervention. However, the implication for an individual is that healthspan (the period of life spent in good health) is a distinct and measurable goal from lifespan. Supporting geroscience research involves advocating for and participating in studies that target fundamental aging processes (like cellular senescence or metabolic regulation) rather than just managing symptoms of single diseases as they appear.

GLP-1 receptor agonists (GLP-1RAs) exert immunoregulatory effects by promoting the polarization of macrophages and microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, thereby reducing neuroinflammation and systemic inflammatory markers.

If you are using a GLP-1RA (like semaglutide or liraglutide) for diabetes or weight loss, understand that it may also be helping to lower systemic inflammation by shifting your immune cells toward a less inflammatory state. This is not just a side effect but a direct mechanism of action on your immune system.

GLP-1RAs modulate T cell differentiation by reducing the proportion of pro-inflammatory Th17 cells and increasing regulatory T cells (Tregs), thereby improving immune tolerance and reducing inflammation in conditions like psoriasis and colitis.

For those with autoimmune conditions, GLP-1RAs may help rebalance your immune system by reducing inflammatory T cells and boosting regulatory ones. This could potentially complement standard treatments by addressing the underlying immune imbalance.

GLP-1RAs reduce innate allergic inflammation and eosinophilia by inhibiting the activity of Group 2 Innate Lymphoid Cells (ILC2s) and reducing the production of type 2 cytokines (IL-5, IL-13).

If you have allergic asthma, GLP-1RAs might help reduce the specific allergic inflammation driven by innate immune cells, potentially easing symptoms beyond just metabolic benefits.

The MAPK signaling pathway (specifically ERK, JNK, and p38) plays a complex, context-dependent role in obesity, regulating appetite, adipogenesis, and insulin resistance, with effects varying between in vitro and in vivo models.

Obesity involves complex signaling networks like MAPK that regulate fat storage and insulin sensitivity. The fact that these pathways have conflicting effects in different contexts explains why single-target interventions often fail and why obesity is a heterogeneous disorder.

GDF15, a member of the TGF-β superfamily, acts as a central regulator of appetite and a potential treatment for obesity by reducing food intake and stimulating lipolysis.

GDF15 is a hormone that reduces food intake and increases fat burning. Research suggests it could be a future treatment for obesity, offering a different mechanism from current drugs.

GLP-1-based therapies and SGLT2 inhibitors provide protective effects on the coronary microvascular compartment in diabetic patients, addressing coronary microvascular dysfunction (CMD).

If you have diabetes and signs of heart issues like chest pain or shortnessess of breath without blocked arteries (CMD), ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs are increasingly recognized to protect the small blood vessels in the heart, beyond just lowering blood sugar.

Endogenous GLP-1 secretion is stimulated by specific nutrient-sensing mechanisms in intestinal L-cells, including SGLT1 and KATP channels for carbohydrates, FFA1 and GPR119 for fats, and Pept1 and CaSR for proteins.

This paper explains the biological 'sensors' in your gut that trigger GLP-1 release when you eat carbs, fats, and proteins. While understanding these mechanisms (like SGLT1 for sugar or GPR119 for fat) is crucial for drug development, there are currently no standard dietary protocols to specifically target these receptors for therapeutic GLP-1 elevation. The paper highlights that while animal models show clear results, human applicability is still being researched.